Search results
Added:
2 weeks ago
Source:
Radcliffe Cardiology
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive disease associated with a significant burden of recurrent cardiovascular (CV) events. A new post hoc analysis of the ATTRibute-CM trial suggests that acoramidis, an oral transthyretin (TTR) stabiliser, significantly reduces the cumulative burden of these outcomes.¹MethodologyThis exploratory analysis used data from the phase 3,…
View more
Added:
10 months ago
HsCRP in ASCVD
Added:
11 months ago
Review Article
Added:
3 months ago
AHA Scientific Sessions 2025 – Late-breaker host Dr Harriette Van Spall (McMaster University, CA) is joined by Dr Erin A Bohula (Brigham & Women's Hospital, US) to discuss the primary results of the VESALIUS-CV trial, a large-scale, phase 3, double-blind, randomised, placebo-controlled study sponsored by Amgen.The VESALIUS-CV trial (NCT03872401) evaluated the impact of evolocumab, a PCSK9…
View more
Added:
6 months ago
ESC Congress 2025 - Long-term beta-blocker therapy after myocardial infarction reduced the primary endpoint of death from any cause or major adverse cardiovascular events.Late-breaker host Dr Harriette Van Spall (McMaster University, CA) sits down with Prof Dan Atar (Oslo University Hospital Ulleval, NO) and Dr Anna Meta Dyrvig Kristensen (Bispebjerg and Frederiksberg Hospital, DK) to discuss the…
View more
Added:
9 months ago
ESC HFA 25 - The WICD-MI study finds heart failure to be frequent in patients with persistent left ventricular dysfunction after acute myocardial infarction.We are joined onsite by Dr Mathieu Echivard (University Hospital of Nancy, Nancy, FR) to discuss key findings from a study investigating heart failure events in patients with persistent left ventricular dysfunction after acute myocardial…
View more
Added:
12 months ago
In this insightful interview, Dr Deepak Bhatt (Mount Sinai Hospital, US) joins us to discuss findings from a post-hoc analysis of the REDUCE-IT trial, examining how icosapent ethyl affects cardiovascular outcomes across different baseline LDL-C levels.The study included 8,175 statin-treated patients with elevated cardiovascular risk and triglyceride levels between 135-499mg/dL. All participants…
View more
Added:
1 year ago
What is the importance of shared decision-making when counselling competitive athletes with cardiovascular abnormalities?In this short interview, Dr Jonathan Kim (Emory University, Atlanta, US) discusses the new scientific statement from AHA and ACC on clinical considerations for practitioners counselling competitive athletes with cardiovascular abnormalities. Dr Kim highlights the statement's…
View more
Added:
6 months ago
ESC Congress 2025 - Pooled MACE Analysis of obicetrapib shows reductions in cardiovascular events and consistent reductions in LDL cholesterol and LP(a).Prof Stephen Nicholls (Monash Victorian Heart Institute, AU) joins us to discuss findings from a pooled major adverse cardiovascular events (MACE) analysis of obicetrapib, examining early signals of cardiovascular benefit in patients with…
View more
Added:
1 year ago
ESC Congress 2024 — The interruption of beta blocker treatment was not non-inferior to a strategy of βB continuation.Host, Dr Harriette Van Spall (McMaster University, Hamilton, CA) sits down with investigator, Prof Johanne Silvain(Pitié-Salpêtrière University Hospital, Paris, FR) to discuss key results from the AβYSS trial (NCT03498066; Assistance Publique - Hôpitaux de Paris).The ABYSS trial…
View more